Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia

References

• Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol. 2002;40:27–33.
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28:1–5.
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504–510.
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
   PubMed Web of Science ®Google Scholar
• Jurkovitz C, Abramson J, McClellan WM. Anemia and cardiovascular and kidney disease. Curr Opin Nephrol Hypertens. 2006;15:117–122.
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381–388.
   PubMed Web of Science ®Google Scholar
• Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207.
   PubMed Web of Science ®Google Scholar
• Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–2925.
   PubMed Web of Science ®Google Scholar
• Brenner BM. Cardiovascular and renal progression factors in chronic kidney disease: A colloquium in honor of John H. Dirks ISN World Congress of Nephrology Singapore, June 26, 2005. Kidney Int. 2005;68:1411–1412.
   PubMed Web of Science ®Google Scholar
• Jun M, Lv J, Perkovic V, Jardine MJ. Managing cardiovascular risk in people with chronic kidney disease: A review of the evidence from randomized controlled trials. Ther Adv Chronic Dis. 2011;2:265–278.
   PubMedGoogle Scholar
• Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239–1247.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–2891.
   PubMed Web of Science ®Google Scholar
• Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62:36–44.
   PubMed Web of Science ®Google Scholar
• Schmidt H, Schmidt R, Niederkorn K, et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study. Stroke. 1998;29:2043–2048.
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–480.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol. 1998;9:319–324.
   PubMed Web of Science ®Google Scholar
• Onat A, Yuksel M, Koroglu B, et al. Turkish Adult Risk Factor Study survey 2012: Overall and coronary mortality and trends in the prevalence of metabolic syndrome. Turk Kardiyoloji Dernegi Arsivi. 2013;41:373–378.
   PubMedGoogle Scholar
• Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis. 2007;191:397–402.
   PubMed Web of Science ®Google Scholar
• Prakash M, Phani NM, Kavya R, Supriya M. Paraoxonase: Its antiatherogenic role in chronic renal failure. Indian J Nephrol. 2010;20:9–14.
   PubMedGoogle Scholar
• Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int. 2008;12:471–479.
   PubMed Web of Science ®Google Scholar
• Dantoine TF, Debord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998;9:2082–2088.
   PubMed Web of Science ®Google Scholar
• Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron. 1998;80:166–170.
   PubMed Web of Science ®Google Scholar
• Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: A population-based ultrasonography study. Atherosclerosis. 1990;81:33–40.
   PubMed Web of Science ®Google Scholar
• Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–2217.
   PubMed Web of Science ®Google Scholar
• Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995;26:386–391.
   PubMed Web of Science ®Google Scholar
• Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation. 1997;96:1432–1437.
   PubMed Web of Science ®Google Scholar
• Aycicek A, Erel O. Total oxidant/antioxidant status in jaundiced newborns before and after phototherapy. J Pediatr. 2007;83:319–322.
   Google Scholar
• Gungor O, Kircelli F, Toz H. Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients. Int Urol Nephrol. 2013;45:441–447.
   PubMed Web of Science ®Google Scholar
• Cece H, Yazgan P, Karakas E, et al. Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis. Clin Invest Med. 2011;34:E225.
   PubMed Web of Science ®Google Scholar
• Kennedy DJ, Tang WH, Fan Y, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013;2:e000104.
   Web of Science ®Google Scholar
• Okuturlar Y, Mert M, Karakaya P, et al. Paraoxonase-1 activity in different patient groups with high risk of atherosclerosis. Acta Med. 2015;31:351.
   Google Scholar
• Michalak S, Kazmierski R, Hellmann A, et al. Serum paraoxonase/arylesterase activity affects outcome in ischemic stroke patients. Cerebrovasc Dis. 2011;32:124–132.
   PubMed Web of Science ®Google Scholar
• Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation. 1997;96:3300–3307.
   PubMed Web of Science ®Google Scholar
• Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1995;141:719–723.
   PubMed Web of Science ®Google Scholar
• Engberink MF, Geleijnse JM, Durga J, et al. Blood donation, body iron status and carotid intima-media thickness. Atherosclerosis. 2008;196:856–862.
   PubMed Web of Science ®Google Scholar
• Sumegová K, Blažíček P, Fuhrman B, Waczulíková I, Ďuračková Z. Paraoxonase 1 (PON1) and its relationship to lipid variables, age and gender in healthy volunteers. Biologia. 2006;61:699–704.
   Web of Science ®Google Scholar